{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T05:28:26Z","timestamp":1781846906828,"version":"3.54.5"},"publisher-location":"Cham","reference-count":102,"publisher":"Springer International Publishing","isbn-type":[{"value":"9783030616625","type":"print"},{"value":"9783030616632","type":"electronic"}],"license":[{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021]]},"DOI":"10.1007\/978-3-030-61663-2_2","type":"book-chapter","created":{"date-parts":[[2021,2,3]],"date-time":"2021-02-03T22:04:45Z","timestamp":1612389885000},"page":"11-25","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Synthetic and Natural Derivatives of Cannabidiol"],"prefix":"10.1007","author":[{"given":"Paula","family":"Morales","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nadine","family":"Jagerovic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,2,4]]},"reference":[{"key":"2_CR1","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1159\/000201556","volume":"83","author":"J Ahrens","year":"2009","unstructured":"Ahrens J, Demir R, Leuwer M et al (2009) The nonpsychotropic cannabinoid cannabidiol modulates and directly activates alpha-1 and alpha-1-beta glycine receptor function. Pharmacology 83:217\u2013222. https:\/\/doi.org\/10.1159\/000201556","journal-title":"Pharmacology"},{"key":"2_CR2","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/j.ejphar.2015.08.021","volume":"765","author":"YM Al Suleimani","year":"2015","unstructured":"Al Suleimani YM, Al Mahruqi AS, Hiley CR (2015) Cardiovascular pharmacology mechanisms of vasorelaxation induced by the cannabidiol analogue compound O-1602 in the rat small mesenteric artery. Eur J Pharmacol 765:107\u2013114. https:\/\/doi.org\/10.1016\/j.ejphar.2015.08.021","journal-title":"Eur J Pharmacol"},{"key":"2_CR3","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1074\/jbc.M111.296020","volume":"287","author":"S Anavi-Goffer","year":"2012","unstructured":"Anavi-Goffer S, Baillie G, Irving AJ et al (2012) Modulation of L-\u03b1-lysophosphatidylinositol\/GPR55 mitogen-activated protein kinase (MAPK) signaling by cannabinoids. J Biol Chem 287:91\u2013104","journal-title":"J Biol Chem"},{"key":"2_CR4","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1055\/s-0037-1598109","volume":"15","author":"CL Anderson","year":"2017","unstructured":"Anderson CL, Evans VF, Demarse TB et al (2017) Cannabidiol for the treatment of drug-resistant epilepsy in children: current state of research. J Pediatr Neurol 15:143\u2013150. https:\/\/doi.org\/10.1055\/s-0037-1598109","journal-title":"J Pediatr Neurol"},{"key":"2_CR5","doi-asserted-by":"publisher","DOI":"10.1021\/acs.orglett.8b01909","volume":"20","author":"SJ Bailey","year":"2018","unstructured":"Bailey SJ, Sapkota RR, Golliher AE et al (2018) Lewis-acid-mediated Union of Epoxy-Carvone Diastereomers with anisole derivatives: mechanistic insight and application to the synthesis of non-natural CBD analogues. Org Lett 20:acs.orglett.8b01909. https:\/\/doi.org\/10.1021\/acs.orglett.8b01909","journal-title":"Org Lett"},{"key":"2_CR6","first-page":"28","volume-title":"International cannabinoid research society","author":"T Bakas","year":"2016","unstructured":"Bakas T, Devenish S, Van Nieuwenhuizen P et al (2016) The actions of cannabidiol and 2-arachidonyl glicerol on GABA-A receptors. In: 26th annual symposium on the cannabinoids. In: International cannabinoid research society. Bukovina, Poland, p 28"},{"key":"2_CR7","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1016\/j.phrs.2017.02.022","volume":"119","author":"T Bakas","year":"2017","unstructured":"Bakas T, van Nieuwenhuijzen PS, Devenish SO et al (2017) The direct actions of cannabidiol and 2-arachidonoyl glycerol at GABAAreceptors. Pharmacol Res 119:358\u2013370. https:\/\/doi.org\/10.1016\/j.phrs.2017.02.022","journal-title":"Pharmacol Res"},{"key":"2_CR8","doi-asserted-by":"publisher","first-page":"2421","DOI":"10.1021\/acs.jcim.5b00280","volume":"55","author":"D Bartuzi","year":"2015","unstructured":"Bartuzi D, Kaczor AA, Matosiuk D (2015) Activation and allosteric modulation of human \u03bc opioid receptor in molecular dynamics. J Chem Inf Model 55:2421\u20132434. https:\/\/doi.org\/10.1021\/acs.jcim.5b00280","journal-title":"J Chem Inf Model"},{"key":"2_CR9","doi-asserted-by":"publisher","first-page":"1113","DOI":"10.1021\/jm050709m","volume":"49","author":"S Ben-Shabat","year":"2006","unstructured":"Ben-Shabat S, Hanu\u0161 LO, Katzavian G, Gallily R (2006) New cannabidiol derivatives: synthesis, binding to cannabinoid receptor, and evaluation of their antiinflammatory activity. J Med Chem 49:1113\u20131117. https:\/\/doi.org\/10.1021\/jm050709m","journal-title":"J Med Chem"},{"key":"2_CR10","doi-asserted-by":"publisher","first-page":"8092","DOI":"10.1523\/JNEUROSCI.2181-06.2006","volume":"26","author":"C Blanco-Centurion","year":"2006","unstructured":"Blanco-Centurion C, Xu M, Murillo-Rodriguez E et al (2006) Adenosine and sleep homeostasis in the basal forebrain. J Neurosci 26:8092\u20138100. https:\/\/doi.org\/10.1523\/JNEUROSCI.2181-06.2006","journal-title":"J Neurosci"},{"key":"2_CR11","doi-asserted-by":"crossref","unstructured":"Bornheim LM, Grillo MP (1998) Characterization of Cytochrome P450 3A Inactivation by Cannabidiol\u00a0: possible Involvement of Cannabidiol-Hydroxyquinone as a P450 Inactivator. 1209\u20131216","DOI":"10.1021\/tx9800598"},{"key":"2_CR12","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0158779","volume":"11","author":"A Breuer","year":"2016","unstructured":"Breuer A, Haj CG, Foga\u00e7a MV et al (2016) Fluorinated Cannabidiol derivatives: enhancement of activity in mice models predictive of anxiolytic, antidepressant and antipsychotic effects. PLoS One 11:e0158779. https:\/\/doi.org\/10.1371\/journal.pone.0158779","journal-title":"PLoS One"},{"key":"2_CR13","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1016\/j.drugalcdep.2017.01.046","volume":"175","author":"SC Britch","year":"2017","unstructured":"Britch SC, Wiley JL, Yu Z et al (2017) Cannabidiol-\u0394 9 -tetrahydrocannabinol interactions on acute pain and locomotor activity. Drug Alcohol Depend 175:187\u2013197. https:\/\/doi.org\/10.1016\/j.drugalcdep.2017.01.046","journal-title":"Drug Alcohol Depend"},{"key":"2_CR14","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1016\/j.bbrc.2017.09.001","volume":"493","author":"KJ Brown","year":"2017","unstructured":"Brown KJ, Laun AS, Song Z (2017) Cannabidiol, a novel inverse agonist for GPR12. Biochem Biophys Res Commun 493:451\u2013454. https:\/\/doi.org\/10.1016\/j.bbrc.2017.09.001","journal-title":"Biochem Biophys Res Commun"},{"key":"2_CR15","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1002\/j.1552-4604.1981.tb02622.x","volume":"21","author":"A Carlini","year":"1981","unstructured":"Carlini A, Cunha M (1981) Hypnotic andAntiepileptic Effectsof Cannabidiol. J Clin Pharmacol 21:417\u2013427","journal-title":"J Clin Pharmacol"},{"key":"2_CR16","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1016\/j.neuropharm.2016.12.017","volume":"116","author":"M Cepri\u00e1n","year":"2017","unstructured":"Cepri\u00e1n M, Jim\u00e9nez-S\u00e1nchez L, Vargas C et al (2017) Cannabidiol reduces brain damage and improves functional recovery in a neonatal rat model of arterial ischemic stroke. Neuropharmacology 116:151\u2013159. https:\/\/doi.org\/10.1016\/j.neuropharm.2016.12.017","journal-title":"Neuropharmacology"},{"key":"2_CR17","doi-asserted-by":"publisher","unstructured":"Chagas MHN, Eckeli AL, Zuardi AW et al (2014) Cannabidiol can improve complex sleep-related behaviours associated with rapid eye movement sleep behaviour disorder in Parkinson\u2019s disease patients: a case series. J Clin Pharm Ther. https:\/\/doi.org\/10.1111\/jcpt.12179","DOI":"10.1111\/jcpt.12179"},{"key":"2_CR18","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1093\/intimm\/dxu097","volume":"27","author":"V Chiurchi\u00f9","year":"2015","unstructured":"Chiurchi\u00f9 V, Lanuti M, De Bardi M et al (2015) The differential characterization of GPR55 receptor in human peripheral blood reveals a distinctive expression in monocytes and NK cells and a proinflammatory role in these innate cells. Int Immunol 27:153\u2013160. https:\/\/doi.org\/10.1093\/intimm\/dxu097","journal-title":"Int Immunol"},{"key":"2_CR19","doi-asserted-by":"publisher","first-page":"3908","DOI":"10.1111\/bph.12746","volume":"171","author":"L Console-Bram","year":"2014","unstructured":"Console-Bram L, Brailoiu E, Brailoiu GC et al (2014) Activation of GPR18 by cannabinoid compounds: a tale of biased agonism. Br J Pharmacol 171:3908\u20133917. https:\/\/doi.org\/10.1111\/bph.12746","journal-title":"Br J Pharmacol"},{"key":"2_CR20","doi-asserted-by":"publisher","first-page":"1479","DOI":"10.1111\/bph.2011.163.issue-7","volume":"163","author":"L De Petrocellis","year":"2011","unstructured":"De Petrocellis L, Ligresti A, Moriello AS et al (2011) Effects of cannabinoids and cannabinoid-enriched cannabis extracts on TRP channels and endocannabinoid metabolic enzymes. Br J Pharmacol 163:1479\u20131494. https:\/\/doi.org\/10.1111\/bph.2011.163.issue-7","journal-title":"Br J Pharmacol"},{"key":"2_CR21","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1111\/j.1748-1716.2011.02338.x","volume":"204","author":"L De Petrocellis","year":"2012","unstructured":"De Petrocellis L, Orlando P, Moriello AS et al (2012) Cannabinoid actions at TRPV channels: effects on TRPV3 and TRPV4 and their potential relevance to gastrointestinal inflammation. Acta Physiol 204:255\u2013266. https:\/\/doi.org\/10.1111\/j.1748-1716.2011.02338.x","journal-title":"Acta Physiol"},{"key":"2_CR22","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.1124\/jpet.107.134809","volume":"325","author":"L De Petrocellis","year":"2008","unstructured":"De Petrocellis L, Vellani V, Schiano-Moriello A et al (2008) Plant-derived cannabinoids modulate the activity of transient receptor potential channels of Ankyrin Type-1 and Melastatin Type-8. J Pharmacol Exp Ther 325:1007\u20131015. https:\/\/doi.org\/10.1124\/jpet.107.134809","journal-title":"J Pharmacol Exp Ther"},{"key":"2_CR23","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/srep21703","volume":"6","author":"C Del R\u00edo","year":"2016","unstructured":"Del R\u00edo C, Navarrete C, Collado JA et al (2016) The cannabinoid quinol VCE-004.8 alleviates bleomycin-induced scleroderma and exerts potent antifibrotic effects through peroxisome proliferator-activated receptor-\u03b3 and CB2 pathways. Sci Rep 6:1\u201314. https:\/\/doi.org\/10.1038\/srep21703","journal-title":"Sci Rep"},{"key":"2_CR24","doi-asserted-by":"publisher","first-page":"8711","DOI":"10.1074\/jbc.M114.618447","volume":"290","author":"MW Elmes","year":"2015","unstructured":"Elmes MW, Kaczocha M, Berger WT et al (2015) Fatty acid-binding proteins (FABPs) are intracellular carriers for \u03949-tetrahydrocannabinol (THC) and cannabidiol (CBD). J Biol Chem 290:8711\u20138721. https:\/\/doi.org\/10.1074\/jbc.M114.618447","journal-title":"J Biol Chem"},{"key":"2_CR25","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0028668","volume":"6","author":"G Esposito","year":"2011","unstructured":"Esposito G, Scuderi C, Valenza M et al (2011) Cannabidiol reduces A\u03b2-induced neuroinflammation and promotes hippocampal neurogenesis through PPAR\u03b3 involvement. PLoS One 6:e28668. https:\/\/doi.org\/10.1371\/journal.pone.0028668","journal-title":"PLoS One"},{"key":"2_CR26","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1111\/j.1365-2125.2012.04341.x","volume":"75","author":"J Fernandez-Ruiz","year":"2013","unstructured":"Fernandez-Ruiz J, Sagredo O, Pazos MR et al (2013) Cannabidiol for neurodegenerative disorders: important new clinical applications for this phytocannabinoid? Br J Clin Pharmacol 75:323\u2013333. https:\/\/doi.org\/10.1111\/j.1365-2125.2012.04341.x","journal-title":"Br J Clin Pharmacol"},{"key":"2_CR27","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/j.neuropharm.2018.03.001","volume":"135","author":"MV Foga\u00e7a","year":"2018","unstructured":"Foga\u00e7a MV, Campos AC, Coelho LD et al (2018) The anxiolytic effects of cannabidiol in chronically stressed mice are mediated by the endocannabinoid system: role of neurogenesis and dendritic remodeling. Neuropharmacology 135:22\u201333. https:\/\/doi.org\/10.1016\/j.neuropharm.2018.03.001","journal-title":"Neuropharmacology"},{"key":"2_CR28","doi-asserted-by":"publisher","first-page":"762","DOI":"10.1111\/j.1476-5381.2010.00743.x","volume":"160","author":"LA Ford","year":"2010","unstructured":"Ford LA, Roelofs AJ, Anavi-Goffer S et al (2010) A role for L-alpha-lysophosphatidylinositol and GPR55 in the modulation of migration, orientation and polarization of human breast cancer cells. Br J Pharmacol 160:762\u2013771. https:\/\/doi.org\/10.1111\/j.1476-5381.2010.00743.x","journal-title":"Br J Pharmacol"},{"key":"2_CR29","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1016\/j.smrv.2014.02.005","volume":"18","author":"PJ Gates","year":"2014","unstructured":"Gates PJ, Albertella L, Copeland J (2014) The effects of cannabinoid administration on sleep: a systematic review of human studies. Sleep Med Rev 18:477\u2013487. https:\/\/doi.org\/10.1016\/j.smrv.2014.02.005","journal-title":"Sleep Med Rev"},{"key":"2_CR30","doi-asserted-by":"publisher","unstructured":"Ghovanloo M-R, Shuart NG, Mezeyova J et al (2018) Inhibitory effects of cannabidiol on voltage-dependent sodium currents. J Biol Chem jbcRA118.004929. https:\/\/doi.org\/10.1074\/JBC.RA118.004929","DOI":"10.1074\/JBC.RA118.004929"},{"key":"2_CR31","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1016\/j.pnpbp.2015.03.017","volume":"64","author":"Y G\u00f3mez-G\u00e1lvez","year":"2016","unstructured":"G\u00f3mez-G\u00e1lvez Y, Palomo-Garo C, Fern\u00e1ndez-Ruiz J, Garc\u00eda C (2016) Potential of the cannabinoid CB2 receptor as a pharmacological target against inflammation in Parkinson\u2019s disease. Prog Neuro-Psychopharmacology Biol Psychiatry 64:200\u2013208. https:\/\/doi.org\/10.1016\/j.pnpbp.2015.03.017","journal-title":"Prog Neuro-Psychopharmacology Biol Psychiatry"},{"key":"2_CR32","doi-asserted-by":"publisher","unstructured":"Gonca E, Dar\u0131c\u0131 F (2014) The effect of Cannabidiol on ischemia\/reperfusion-induced ventricular arrhythmias: the role of adenosine A1 receptors. J Cardiovasc Pharmacol Ther (1):76. https:\/\/doi.org\/10.1177\/1074248414532013","DOI":"10.1177\/1074248414532013"},{"key":"2_CR33","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1016\/S0306-4522(02)00034-9","volume":"111","author":"C Gottesmann","year":"2002","unstructured":"Gottesmann C (2002) GABA mechanisms and sleep. Neuroscience 111:231\u2013239. https:\/\/doi.org\/10.1016\/S0306-4522(02)00034-9","journal-title":"Neuroscience"},{"key":"2_CR34","doi-asserted-by":"publisher","first-page":"118","DOI":"10.5698\/1535-7597.18.2.118","volume":"18","author":"A Gupta","year":"2018","unstructured":"Gupta A, Santhakumar V (2018) Reefer to the rescue: the dope on cannabidiol as a multi- symptom panacea for Dravet syndrome. Epilepsy Curr 18:118\u2013120. https:\/\/doi.org\/10.5698\/1535-7597.18.2.118","journal-title":"Epilepsy Curr"},{"key":"2_CR35","doi-asserted-by":"publisher","unstructured":"Hardman JM, Brooke RT, Zipp BJ (2017) Cannabinoid glycosides: in vitro production of a new class of cannabinoids with improved physicochemical properties. BioRxiv Pre-Print. https:\/\/doi.org\/10.1101\/104349","DOI":"10.1101\/104349"},{"key":"2_CR36","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1016\/j.braindev.2018.03.013","volume":"40","author":"M Hausman-Kedem","year":"2018","unstructured":"Hausman-Kedem M, Menascu S, Kramer U (2018) Efficacy of CBD-enriched medical cannabis for treatment of refractory epilepsy in children and adolescents \u2013 an observational, longitudinal study. Brain and Development 40:544\u2013551. https:\/\/doi.org\/10.1016\/j.braindev.2018.03.013","journal-title":"Brain and Development"},{"key":"2_CR37","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1089\/can.2016.0037","volume":"2","author":"MS Ibsen","year":"2017","unstructured":"Ibsen MS, Connor M, Glass M (2017) Cannabinoid CB1 and CB2 receptor signaling and bias. Cannabis Cannabinoid Res 2:48\u201360. https:\/\/doi.org\/10.1089\/can.2016.0037","journal-title":"Cannabis Cannabinoid Res"},{"key":"2_CR38","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1016\/j.neulet.2010.12.031","volume":"490","author":"B Ignatowska-Jankowska","year":"2011","unstructured":"Ignatowska-Jankowska B, Jankowski MM, Swiergiel AH (2011) Cannabidiol decreases body weight gain in rats: involvement of CB2 receptors. Neurosci Lett 490:82\u201384. https:\/\/doi.org\/10.1016\/j.neulet.2010.12.031","journal-title":"Neurosci Lett"},{"key":"2_CR39","doi-asserted-by":"crossref","unstructured":"Irving A, Abdulrazzaq G, Chan SLF et al (2017) Cannabinoid receptor-related orphan G protein-coupled receptors, 1st edn. Elsevier Inc","DOI":"10.1016\/bs.apha.2017.04.004"},{"key":"2_CR40","doi-asserted-by":"publisher","first-page":"332","DOI":"10.2133\/dmpk.DMPK-12-RG-129","volume":"28","author":"R Jiang","year":"2013","unstructured":"Jiang R, Yamaori S, Okamoto Y et al (2013) Cannabidiol is a potent inhibitor of the catalytic activity of cytochrome P450 2C19. Drug Metab Pharmacokinet 28:332\u2013338. https:\/\/doi.org\/10.2133\/dmpk.DMPK-12-RG-129","journal-title":"Drug Metab Pharmacokinet"},{"key":"2_CR41","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1016\/j.lfs.2011.05.018","volume":"89","author":"R Jiang","year":"2011","unstructured":"Jiang R, Yamaori S, Takeda S et al (2011) Identification of cytochrome P450 enzymes responsible for metabolism of cannabidiol by human liver microsomes. Life Sci 89:165\u2013170. https:\/\/doi.org\/10.1016\/j.lfs.2011.05.018","journal-title":"Life Sci"},{"key":"2_CR42","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1038\/sj.bjp.0707419","volume":"152","author":"DG Johns","year":"2007","unstructured":"Johns DG, Behm DJ, Walker DJ et al (2007) The novel endocannabinoid receptor GPR55 is activated by atypical cannabinoids but does not mediate their vasodilator effects. Br J Pharmacol 152:825\u2013831. https:\/\/doi.org\/10.1038\/sj.bjp.0707419","journal-title":"Br J Pharmacol"},{"key":"2_CR43","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1007\/s00210-006-0033-x","volume":"372","author":"M Kathmann","year":"2006","unstructured":"Kathmann M, Flau K, Redmer A et al (2006) Cannabidiol is an allosteric modulator at mu- and delta-opioid receptors. Naunyn Schmiedeberg's Arch Pharmacol 372:354\u2013361. https:\/\/doi.org\/10.1007\/s00210-006-0033-x","journal-title":"Naunyn Schmiedeberg's Arch Pharmacol"},{"key":"2_CR44","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1007\/s00213-011-2342-0","volume":"218","author":"C Klein","year":"2011","unstructured":"Klein C, Karanges E, Spiro A et al (2011) Cannabidiol potentiates \u0394 9-tetrahydrocannabinol (THC) behavioural effects and alters THC pharmacokinetics during acute and chronic treatment in adolescent rats. Psychopharmacology 218:443\u2013457. https:\/\/doi.org\/10.1007\/s00213-011-2342-0","journal-title":"Psychopharmacology"},{"key":"2_CR45","doi-asserted-by":"publisher","first-page":"4790","DOI":"10.1111\/bph.13250","volume":"20","author":"RB Laprairie","year":"2015","unstructured":"Laprairie RB, Bagher AM, Kelly MEM, Denovan-Wright EM (2015) Cannabidiol is a negative allosteric modulator of the type 1 cannabinoid receptor. Br J Pharmacol 20:4790\u20134805. https:\/\/doi.org\/10.1111\/bph.13250","journal-title":"Br J Pharmacol"},{"key":"2_CR46","doi-asserted-by":"publisher","unstructured":"Laun AS, Song Z-H (2017) GPR3 and GPR6, novel molecular targets for cannabidiol. Biochem Biophys Res Commun. https:\/\/doi.org\/10.1016\/j.bbrc.2017.05.165","DOI":"10.1016\/j.bbrc.2017.05.165"},{"key":"2_CR47","doi-asserted-by":"publisher","unstructured":"Leweke FM, Piomelli D, Pahlisch F et al (2012) Cannabidiol enhances anandamide signaling and alleviates psychotic symptoms of schizophrenia. Transl Psychiatry 2. https:\/\/doi.org\/10.1038\/tp.2012.15","DOI":"10.1038\/tp.2012.15"},{"key":"2_CR48","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1177\/0883073818773028","volume":"33","author":"S Libzon","year":"2018","unstructured":"Libzon S, Schleider LB-L, Saban N et al (2018) Medical cannabis for pediatric moderate to severe complex motor disorders. J Child Neurol 33:565\u2013571. https:\/\/doi.org\/10.1177\/0883073818773028","journal-title":"J Child Neurol"},{"key":"2_CR49","doi-asserted-by":"publisher","first-page":"315","DOI":"10.3389\/fphar.2018.00315","volume":"9","author":"IMP Linares","year":"2018","unstructured":"Linares IMP, Guimaraes FS, Eckeli A et al (2018) No acute effects of Cannabidiol on the sleep-wake cycle of healthy subjects: a randomized, double-blind, placebo-controlled, crossover study. Front Pharmacol 9:315. https:\/\/doi.org\/10.3389\/fphar.2018.00315","journal-title":"Front Pharmacol"},{"key":"2_CR50","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1016\/j.ejphar.2013.10.011","volume":"720","author":"M Mahgoub","year":"2013","unstructured":"Mahgoub M, Keun-Hang SY, Sydorenko V et al (2013) Effects of cannabidiol on the function of \u03b17-nicotinic acetylcholine receptors. Eur J Pharmacol 720:310\u2013319. https:\/\/doi.org\/10.1016\/j.ejphar.2013.10.011","journal-title":"Eur J Pharmacol"},{"key":"2_CR51","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1017\/S2045796018000239","volume":"27","author":"GM Mandolini","year":"2018","unstructured":"Mandolini GM, Lazzaretti M, Pigoni A et al (2018) Pharmacological properties of cannabidiol in the treatment of psychiatric disorders: a critical overview. Epidemiol Psychiatr Sci 27:327\u2013335. https:\/\/doi.org\/10.1017\/S2045796018000239","journal-title":"Epidemiol Psychiatr Sci"},{"key":"2_CR52","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fphar.2017.00744","volume":"8","author":"E Mart\u00ednez-Pinilla","year":"2017","unstructured":"Mart\u00ednez-Pinilla E, Varani K, Reyes-Resina I et al (2017) Binding and signaling studies disclose a potential allosteric site for Cannabidiol in cannabinoid CB2 receptors. Front Pharmacol 8:1\u201310. https:\/\/doi.org\/10.3389\/fphar.2017.00744","journal-title":"Front Pharmacol"},{"key":"2_CR53","doi-asserted-by":"publisher","first-page":"2414","DOI":"10.1111\/j.1476-5381.2011.01497.x","volume":"165","author":"D McHugh","year":"2012","unstructured":"McHugh D, Page J, Dunn E, Bradshaw HB (2012) \u03949-Tetrahydrocannabinol and N-arachidonyl glycine are full agonists at GPR18 receptors and induce migration in human endometrial HEC-1B cells. Br J Pharmacol 165:2414\u20132424. https:\/\/doi.org\/10.1111\/j.1476-5381.2011.01497.x","journal-title":"Br J Pharmacol"},{"key":"2_CR54","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fphar.2013.00162","volume":"4","author":"D McHugh","year":"2014","unstructured":"McHugh D, Roskowski D, Xie S, Bradshaw HB (2014) \u03949-THC and N-arachidonoyl glycine regulate BV-2 microglial morphology and cytokine release plasticity: implications for signaling at GPR18. Front Pharmacol 4:1\u20138. https:\/\/doi.org\/10.3389\/fphar.2013.00162","journal-title":"Front Pharmacol"},{"key":"2_CR55","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1038\/sj.bjp.0707399","volume":"152","author":"JM McPartland","year":"2007","unstructured":"McPartland JM, Glass M, Pertwee RG (2007) Meta-analysis of cannabinoid ligand binding affinity and receptor distribution: interspecies differences. Br J Pharmacol 152:583\u2013593. https:\/\/doi.org\/10.1038\/sj.bjp.0707399","journal-title":"Br J Pharmacol"},{"key":"2_CR56","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1089\/can.2015.0005","volume":"1","author":"P Morales","year":"2016","unstructured":"Morales P, Goya P, Jagerovic N, Hernandez-Folgado L (2016) Allosteric modulators of the CB1 cannabinoid receptor: a structural update review. Cannabis Cannabinoid Res 1:22\u201330","journal-title":"Cannabis Cannabinoid Res"},{"key":"2_CR57","doi-asserted-by":"publisher","unstructured":"Morales P, Isawi I, Reggio PH (2018) Towards a better understanding of the cannabinoid-related orphan receptors GPR3, GPR6, and GPR12. Drug Metab Rev:1\u201320. https:\/\/doi.org\/10.1080\/03602532.2018.1428616","DOI":"10.1080\/03602532.2018.1428616"},{"key":"2_CR58","doi-asserted-by":"publisher","first-page":"2087","DOI":"10.2174\/0929867323666160425113836","volume":"23","author":"P Morales","year":"2016","unstructured":"Morales P, Jagerovic N (2016) Advances towards the discovery of GPR55 ligands. Curr Med Chem 23:2087\u20132100","journal-title":"Curr Med Chem"},{"key":"2_CR59","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1089\/can.2017.0036","volume":"2","author":"P Morales","year":"2017","unstructured":"Morales P, Reggio PH (2017) An update on non-CB1, non-CB2 cannabinoid related G-protein-coupled receptors. Cannabis Cannabinoid Res 2:265\u2013273. https:\/\/doi.org\/10.1089\/can.2017.0036","journal-title":"Cannabis Cannabinoid Res"},{"key":"2_CR60","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fphar.2017.00422","volume":"8","author":"P Morales","year":"2017","unstructured":"Morales P, Reggio PH, Jagerovic N (2017) An overview on medicinal chemistry of synthetic and natural derivatives of Cannabidiol. Front Pharmacol 8:1\u201318. https:\/\/doi.org\/10.3389\/fphar.2017.00422","journal-title":"Front Pharmacol"},{"key":"2_CR61","doi-asserted-by":"publisher","first-page":"1420","DOI":"10.1016\/j.pnpbp.2008.04.008","volume":"32","author":"E Murillo-Rodr\u00edguez","year":"2008","unstructured":"Murillo-Rodr\u00edguez E (2008) The role of the CB1receptor in the regulation of sleep. Prog Neuro-Psychopharmacology Biol Psychiatry 32:1420\u20131427. https:\/\/doi.org\/10.1016\/j.pnpbp.2008.04.008","journal-title":"Prog Neuro-Psychopharmacology Biol Psychiatry"},{"key":"2_CR62","doi-asserted-by":"publisher","first-page":"1511","DOI":"10.1007\/s11064-018-2565-0","volume":"43","author":"E Murillo-Rodr\u00edguez","year":"2018","unstructured":"Murillo-Rodr\u00edguez E, Arankowsky-Sandoval G, Rocha NB et al (2018) Systemic injections of Cannabidiol enhance acetylcholine levels from basal forebrain in rats. Neurochem Res 43:1511\u20131518. https:\/\/doi.org\/10.1007\/s11064-018-2565-0","journal-title":"Neurochem Res"},{"key":"2_CR63","doi-asserted-by":"publisher","first-page":"4337","DOI":"10.1016\/j.febslet.2006.04.102","volume":"580","author":"E Murillo-Rodr\u00edguez","year":"2006","unstructured":"Murillo-Rodr\u00edguez E, Mill\u00e1n-Aldaco D, Palomero-Rivero M et al (2006) Cannabidiol, a constituent of Cannabis sativa, modulates sleep in rats. FEBS Lett 580:4337\u20134345. https:\/\/doi.org\/10.1016\/j.febslet.2006.04.102","journal-title":"FEBS Lett"},{"key":"2_CR64","doi-asserted-by":"publisher","first-page":"1378","DOI":"10.1037\/a0013278","volume":"122","author":"E Murillo-Rodr\u00edguez","year":"2008","unstructured":"Murillo-Rodr\u00edguez E, Mill\u00e1n-Aldaco D, Palomero-Rivero M et al (2008) The nonpsychoactive cannabis constituent cannabidiol is a wake-inducing agent. Behav Neurosci 122:1378\u20131382. https:\/\/doi.org\/10.1037\/a0013278","journal-title":"Behav Neurosci"},{"key":"2_CR65","doi-asserted-by":"crossref","unstructured":"Murillo-Rodr\u00edguez E, Sarro-Ram\u00edrez A, S\u00e1nchez D, et al (2014) Potential effects of Cannabidiol as a wake-promoting agent","DOI":"10.2174\/1570159X11666131204235805"},{"key":"2_CR66","doi-asserted-by":"publisher","DOI":"10.1186\/s12974-018-1103-y","volume":"15","author":"C Navarrete","year":"2018","unstructured":"Navarrete C, Carrillo-Salinas F, Palomares B et al (2018) Hypoxia mimetic activity of VCE-004.8, a cannabidiol quinone derivative: implications for multiple sclerosis therapy. J Neuroinflammation 15:64. https:\/\/doi.org\/10.1186\/s12974-018-1103-y","journal-title":"J Neuroinflammation"},{"key":"2_CR67","doi-asserted-by":"publisher","unstructured":"Navarro G, Reyes-Resina I, Rivas-Santisteban R, et al (2018) Cannabidiol skews biased agonism at cannabinoid CB1 and CB2 receptors with smaller effect in CB1-CB2 heteroreceptor complexes. Biochem Pharmacol. In press doi: https:\/\/doi.org\/10.1016\/j.bcp.2018.08.046","DOI":"10.1016\/j.bcp.2018.08.046"},{"key":"2_CR68","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1016\/j.yebeh.2018.02.009","volume":"81","author":"D Neubauer","year":"2018","unstructured":"Neubauer D, Perkovi\u0107 Benedik M, Osredkar D (2018) Cannabidiol for treatment of refractory childhood epilepsies: experience from a single tertiary epilepsy center in Slovenia. Epilepsy Behav 81:79\u201385. https:\/\/doi.org\/10.1016\/j.yebeh.2018.02.009","journal-title":"Epilepsy Behav"},{"key":"2_CR69","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1097\/01.jcp.0000125688.05091.8f","volume":"24","author":"AN Nicholson","year":"2004","unstructured":"Nicholson AN, Turner C, Stone BM, Robson PJ (2004) Effect of delta-9-Tetrahydrocannabinol and Cannabidiol on nocturnal sleep and early-morning behavior in young adults. J Clin Psychopharmacol 24:305\u2013313. https:\/\/doi.org\/10.1097\/01.jcp.0000125688.05091.8f","journal-title":"J Clin Psychopharmacol"},{"key":"2_CR70","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/j.ejphar.2009.03.010","volume":"612","author":"SE O\u2019Sullivan","year":"2009","unstructured":"O\u2019Sullivan SE, Sun Y, Bennett AJ et al (2009) Time-dependent vascular actions of cannabidiol in the rat aorta. Eur J Pharmacol 612:61\u201368. https:\/\/doi.org\/10.1016\/j.ejphar.2009.03.010","journal-title":"Eur J Pharmacol"},{"key":"2_CR71","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/S0014-2999(02)02624-9","volume":"456","author":"RG Pertwee","year":"2002","unstructured":"Pertwee RG, Ross RA, Craib SJ, Thomas A (2002) (\u2212)-Cannabidiol antagonizes cannabinoid receptor agonists and noradrenaline in the mouse vas deferens. Eur J Pharmacol 456:99\u2013106. https:\/\/doi.org\/10.1016\/S0014-2999(02)02624-9","journal-title":"Eur J Pharmacol"},{"key":"2_CR72","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1016\/j.pharmthera.2017.02.041","volume":"175","author":"S Pisanti","year":"2017","unstructured":"Pisanti S, Malfitano AM, Ciaglia E et al (2017) Cannabidiol: state of the art and new challenges for therapeutic applications. Pharmacol Ther 175:133\u2013150. https:\/\/doi.org\/10.1016\/j.pharmthera.2017.02.041","journal-title":"Pharmacol Ther"},{"key":"2_CR73","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1124\/jpet.115.230151","volume":"357","author":"DS Reddy","year":"2016","unstructured":"Reddy DS, Golub VM (2016) The pharmacological basis of cannabis therapy for epilepsy. J Pharmacol Exp Ther 357:45\u201355. https:\/\/doi.org\/10.1124\/jpet.115.230151","journal-title":"J Pharmacol Exp Ther"},{"key":"2_CR74","doi-asserted-by":"publisher","first-page":"2620","DOI":"10.1111\/j.1476-5381.2011.01621.x","volume":"165","author":"EM Rock","year":"2012","unstructured":"Rock EM, Bolognini D, Limebeer CL et al (2012) Cannabidiol, a nonpsychotropic component of cannabis, attenuates vomiting and nausea-like behaviour via indirect agonism of 5-HT 1A somatodendritic autoreceptors in the dorsal raphe nucleus. Br J Pharmacol 165:2620\u20132634. https:\/\/doi.org\/10.1111\/j.1476-5381.2011.01621.x","journal-title":"Br J Pharmacol"},{"key":"2_CR102","unstructured":"Roehrs T (2010) Medications and sleep. In: Roehrs T (ed). Elsevier health sciences, London, UK. ISBN 9781455700653"},{"key":"2_CR75","doi-asserted-by":"publisher","first-page":"1037","DOI":"10.1007\/s11064-005-6978-1","volume":"30","author":"EB Russo","year":"2005","unstructured":"Russo EB, Burnett A, Hall B, Parker KK (2005) Agonistic properties of cannabidiol at 5-HT1a receptors. Neurochem Res 30:1037\u20131043. https:\/\/doi.org\/10.1007\/s11064-005-6978-1","journal-title":"Neurochem Res"},{"key":"2_CR76","doi-asserted-by":"publisher","first-page":"1729","DOI":"10.1002\/cbdv.200790150","volume":"4","author":"EB Russo","year":"2007","unstructured":"Russo EB, Guy GW, Robson PJ (2007) Cannabis, pain, and sleep: lessons from therapeutic clinical trials of sativex, a cannabis-based medicine. Chem Biodivers 4:1729\u20131743. https:\/\/doi.org\/10.1002\/cbdv.200790150","journal-title":"Chem Biodivers"},{"key":"2_CR77","doi-asserted-by":"publisher","first-page":"1092","DOI":"10.1038\/sj.bjp.0707460","volume":"152","author":"E Ryberg","year":"2007","unstructured":"Ryberg E, Larsson N, Sj\u00f6gren S et al (2007) The orphan receptor GPR55 is a novel cannabinoid receptor. Br J Pharmacol 152:1092\u20131101. https:\/\/doi.org\/10.1038\/sj.bjp.0707460","journal-title":"Br J Pharmacol"},{"key":"2_CR78","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.1002\/ptr.5095","volume":"28","author":"C Scuderi","year":"2014","unstructured":"Scuderi C, Steardo L, Esposito G (2014) Cannabidiol promotes amyloid precursor protein ubiquitination and reduction of beta amyloid expression in SHSY5YAPP+ cells through PPARg involvement. Phyther Res 28:1007\u20131013. https:\/\/doi.org\/10.1002\/ptr.5095","journal-title":"Phyther Res"},{"key":"2_CR79","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1016\/j.pnpbp.2017.07.012","volume":"79","author":"NR Silva","year":"2017","unstructured":"Silva NR, Gomes FV, Fonseca MD et al (2017) Antinociceptive effects of HUF-101, a fluorinated cannabidiol derivative. Prog Neuro-Psychopharmacology Biol Psychiatry 79:369\u2013377. https:\/\/doi.org\/10.1016\/j.pnpbp.2017.07.012","journal-title":"Prog Neuro-Psychopharmacology Biol Psychiatry"},{"key":"2_CR80","doi-asserted-by":"publisher","unstructured":"Smith JS, Lefkowitz RJ, Rajagopal S (2018) Biased signalling: from simple switches to allosteric microprocessors. Nat Rev Drug Discov. https:\/\/doi.org\/10.1038\/nrd.2017.229","DOI":"10.1038\/nrd.2017.229"},{"key":"2_CR81","doi-asserted-by":"publisher","first-page":"86","DOI":"10.3109\/03602532.2013.849268","volume":"46","author":"SM Stout","year":"2014","unstructured":"Stout SM, Cimino NM (2014) Exogenous cannabinoids as substrates, inhibitors, and inducers of human drug metabolizing enzymes: a systematic review. Drug Metab Rev 46:86\u201395. https:\/\/doi.org\/10.3109\/03602532.2013.849268","journal-title":"Drug Metab Rev"},{"key":"2_CR82","doi-asserted-by":"publisher","first-page":"985","DOI":"10.1002\/art.20050","volume":"50","author":"PF Sumariwalla","year":"2004","unstructured":"Sumariwalla PF, Gallily R, Tchilibon S et al (2004) A novel synthetic, nonpsychoactive cannabinoid acid ( HU-320 ) with Antiinflammatory properties in murine collagen-induced arthritis. Arthitis Rheum 50:985\u2013998. https:\/\/doi.org\/10.1002\/art.20050","journal-title":"Arthitis Rheum"},{"key":"2_CR83","doi-asserted-by":"publisher","first-page":"1252","DOI":"10.1016\/j.drudis.2011.09.009","volume":"34","author":"S Takeda","year":"2011","unstructured":"Takeda S, Hirayama A, Urata S et al (2011) Cannabidiol-2\u2032,6\u2032-dimethyl ether as an effective protector of 15- Lipoxygenase-mediated low-density lipoprotein oxidation in vitro. Biol Pharm Bull 34:1252\u20131256. https:\/\/doi.org\/10.1016\/j.drudis.2011.09.009","journal-title":"Biol Pharm Bull"},{"key":"2_CR84","doi-asserted-by":"publisher","first-page":"739","DOI":"10.2131\/jts.40.739","volume":"40","author":"S Takeda","year":"2015","unstructured":"Takeda S, Hirota R, Teradaira S et al (2015) Cannabidiol-2\u2032,6\u2032-dimethyl ether stimulates body weight gain in apolipoprotein E-deficient BALB\/c. KOR\/Stm Slc-Apoe(shl) mice. J Toxicol Sci 40:739\u2013743. https:\/\/doi.org\/10.2131\/jts.40.739","journal-title":"J Toxicol Sci"},{"key":"2_CR85","doi-asserted-by":"crossref","unstructured":"Takeda S, Watanabe K, Aramaki H (2017) Phytocannabinoids, \u0394 9 -tetrahydrocannabinol and cannabidiol, as human calpain-1 (CAPN1) activators. 4:101\u2013103","DOI":"10.2131\/fts.4.101"},{"key":"2_CR86","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1007\/BF00233147","volume":"15","author":"H Tanaka","year":"1996","unstructured":"Tanaka H, Takahashi R, Morimoto S, Shoyama Y (1996) Cannabis 25, biotransformation of cannabidiol and cannabidiolic acid by Pinellia ternata tissue segments. Plant Cell Rep 15:819\u2013823","journal-title":"Plant Cell Rep"},{"key":"2_CR87","doi-asserted-by":"publisher","unstructured":"Tham M, Yilmaz O, Alaverdashvili M, et al (2018) Allosteric and orthosteric pharmacology of cannabidiol and cannabidiol-dimethylheptyl at the type 1 and type 2 cannabinoid receptors. Br J Pharmacol in revision doi: https:\/\/doi.org\/10.1111\/bph.14440","DOI":"10.1111\/bph.14440"},{"key":"2_CR88","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1038\/sj.bjp.0707133","volume":"150","author":"A Thomas","year":"2007","unstructured":"Thomas A, Baillie GL, Phillips AM et al (2007) Cannabidiol displays unexpectedly high potency as an antagonist of CB1 and CB2 receptor agonists in vitro. Br J Pharmacol 150:613\u2013623. https:\/\/doi.org\/10.1038\/sj.bjp.0707133","journal-title":"Br J Pharmacol"},{"key":"2_CR89","doi-asserted-by":"publisher","first-page":"1641","DOI":"10.1248\/cpb.47.1641","volume":"47","author":"N Usami","year":"1999","unstructured":"Usami N, Okuda T, Yoshida H et al (1999) Synthesis and pharmacological evaluation in mice of halogenated cannabidiol derivatives. Chem Pharm Bull (Tokyo) 47:1641\u20131645","journal-title":"Chem Pharm Bull (Tokyo)"},{"key":"2_CR90","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1007\/s00213-006-0356-9","volume":"186","author":"SA Varvel","year":"2006","unstructured":"Varvel SA, Wiley JL, Yang R et al (2006) Interactions between THC and cannabidiol in mouse models of cannabinoid activity. Psychopharmacology 186:226\u2013234. https:\/\/doi.org\/10.1007\/s00213-006-0356-9","journal-title":"Psychopharmacology"},{"key":"2_CR91","doi-asserted-by":"crossref","unstructured":"Wheal AJ, Cipriano M, Fowler CJ, et al (2014) Cannabidiol Improves Vasorelaxation in Zucker Diabetic Fatty Rats through Cyclooxygenase Activation. 457\u2013466","DOI":"10.1124\/jpet.114.217125"},{"key":"2_CR92","doi-asserted-by":"publisher","first-page":"16511","DOI":"10.1073\/pnas.0902743106","volume":"106","author":"LS Whyte","year":"2009","unstructured":"Whyte LS, Ryberg E, Sims NA et al (2009) The putative cannabinoid receptor GPR55 affects osteoclast function in vitro and bone mass in vivo. Proc Natl Acad Sci U S A 106:16511\u201316516. https:\/\/doi.org\/10.1073\/pnas.0902743106","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2_CR93","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1021\/acs.chemrestox.7b00302","volume":"31","author":"JT Wilson","year":"2018","unstructured":"Wilson JT, Fief CA, Jackson KD et al (2018) HU-331 and oxidized Cannabidiol act as inhibitors of human topoisomerase II\u03b1 and \u03b2. Chem Res Toxicol 31:137\u2013144. https:\/\/doi.org\/10.1021\/acs.chemrestox.7b00302","journal-title":"Chem Res Toxicol"},{"key":"2_CR94","doi-asserted-by":"publisher","first-page":"1121","DOI":"10.1084\/jem.20120242","volume":"209","author":"W Xiong","year":"2012","unstructured":"Xiong W, Cui T, Cheng K et al (2012) Cannabinoids suppress inflammatory and neuropathic pain by targeting alpha3 glycine receptors. J Exp Med 209:1121\u20131134. https:\/\/doi.org\/10.1084\/jem.20120242","journal-title":"J Exp Med"},{"key":"2_CR95","doi-asserted-by":"publisher","first-page":"730","DOI":"10.1016\/j.lfs.2011.02.017","volume":"88","author":"S Yamaori","year":"2011","unstructured":"Yamaori S, Ebisawa J, Okushima Y et al (2011) Potent inhibition of human cytochrome P450 3A isoforms by cannabidiol: role of phenolic hydroxyl groups in the resorcinol moiety. Life Sci 88:730\u2013736. https:\/\/doi.org\/10.1016\/j.lfs.2011.02.017","journal-title":"Life Sci"},{"key":"2_CR96","doi-asserted-by":"publisher","first-page":"1691","DOI":"10.1016\/j.bcp.2010.01.028","volume":"79","author":"S Yamaori","year":"2010","unstructured":"Yamaori S, Kushihara M, Yamamoto I, Watanabe K (2010) Characterization of major phytocannabinoids, cannabidiol and cannabinol, as isoform-selective and potent inhibitors of human CYP1 enzymes. Biochem Pharmacol 79:1691\u20131698. https:\/\/doi.org\/10.1016\/j.bcp.2010.01.028","journal-title":"Biochem Pharmacol"},{"key":"2_CR97","doi-asserted-by":"publisher","first-page":"2049","DOI":"10.1124\/dmd.111.041384","volume":"39","author":"S Yamaori","year":"2011","unstructured":"Yamaori S, Okamoto Y, Yamamoto I, Watanabe K (2011) Cannabidiol, a major phytocannabinoid, as a potent atypical inhibitor for CYP2D6. Drug Metab Dispos 39:2049\u20132056. https:\/\/doi.org\/10.1124\/dmd.111.041384","journal-title":"Drug Metab Dispos"},{"key":"2_CR98","doi-asserted-by":"publisher","first-page":"1197","DOI":"10.1248\/bpb.b13-00183","volume":"36","author":"S Yamaori","year":"2013","unstructured":"Yamaori S, Okushima Y, Masuda K et al (2013) Structural requirements for potent direct inhibition of human cytochrome P450 1A1 by Cannabidiol: role of Pentylresorcinol moiety. Biol Pharm Bull 36:1197\u20131203. https:\/\/doi.org\/10.1248\/bpb.b13-00183","journal-title":"Biol Pharm Bull"},{"key":"2_CR99","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1016\/j.cbi.2014.03.007","volume":"215","author":"S Yamaori","year":"2014","unstructured":"Yamaori S, Okushima Y, Yamamoto I, Watanabe K (2014) Characterization of the structural determinants required for potent mechanism-based inhibition of human cytochrome P450 1A1 by cannabidiol. Chem Biol Interact 215:62\u201368. https:\/\/doi.org\/10.1016\/j.cbi.2014.03.007","journal-title":"Chem Biol Interact"},{"key":"2_CR100","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1124\/jpet.109.162594","volume":"333","author":"K-H Yang","year":"2010","unstructured":"Yang K-H, Galadari S, Isaev D et al (2010) The nonpsychoactive cannabinoid cannabidiol inhibits 5-hydroxytryptamine3A receptor-mediated currents in Xenopus laevis oocytes. J Pharmacol Exp Ther 333:547\u2013554. https:\/\/doi.org\/10.1124\/jpet.109.162594","journal-title":"J Pharmacol Exp Ther"},{"key":"2_CR101","doi-asserted-by":"publisher","first-page":"206","DOI":"10.4161\/auto.5223","volume":"17","author":"O Zendulka","year":"2016","unstructured":"Zendulka O, Dovrtelov\u00e1 G, Noskov\u00e1 K et al (2016) Cannabinoids and cytochrome P450 interactions. Curr Drug Metab 17:206\u2013226. https:\/\/doi.org\/10.4161\/auto.5223","journal-title":"Curr Drug Metab"}],"container-title":["Advances in Experimental Medicine and Biology","Cannabinoids and Sleep"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/978-3-030-61663-2_2","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,24]],"date-time":"2021-09-24T03:46:40Z","timestamp":1632455200000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/978-3-030-61663-2_2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021]]},"ISBN":["9783030616625","9783030616632"],"references-count":102,"URL":"https:\/\/doi.org\/10.1007\/978-3-030-61663-2_2","relation":{},"ISSN":["0065-2598","2214-8019"],"issn-type":[{"value":"0065-2598","type":"print"},{"value":"2214-8019","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021]]},"assertion":[{"value":"4 February 2021","order":1,"name":"first_online","label":"First Online","group":{"name":"ChapterHistory","label":"Chapter History"}}]}}